re: Ann: Letter to Shareholders from the Boar... Gents
lets not get to excited about isentress...
it was raised by the EGM shareholders simply because it is not a fixed dose combo but is making money as a twice a day drug with a larger dose...
the EGM shareholders letter was to highlight that twice a day ARVs listed for salvage therapy can still be successfully launched and make money...
end of story...
drongo's bumbling page on isentress is a waste of time
About 40% of patients in the Phase III studies for Isentress did NOT achieve an undetectable viral load.
And many more that did achieve an undetectable viral load became resistant very quickly...
The safety profile of isentress and ATC are similar, ATC also has no impact on cardiovascular parameters, cholesterol or insulin.
There is also no reason that ATC could not also be prescribed off label and enjoy additional sales in the same manner.
Admiral DRONGO, with your letter last friday, either you are trying to decieve Shareholders about the true worth of ATC, or you have been deceiving Shareholders all along as you raised our money for the 'top clinical jewel'
('top clinical jewel' was a drongo statement made in Nov 2008, not even 2 yrs ago...).
DRONGO MUST GO
NEVER TO BE SEEN AGAIN
VOTE NOW FOR ALL RESOLUTIONS
Add to My Watchlist
What is My Watchlist?